Abeona Therapeutics Inc (NASDAQ:ABEO) Director Mark Alvino Sells 4,000 Shares of Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) Director Mark Alvino sold 4,000 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $5.10, for a total transaction of $20,400.00. Following the transaction, the director now directly owns 68,334 shares in the company, valued at $348,503.40. The trade was a 5.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Abeona Therapeutics Price Performance

Abeona Therapeutics stock opened at $5.19 on Wednesday. The business’s 50 day simple moving average is $5.81 and its 200 day simple moving average is $5.72. Abeona Therapeutics Inc has a 12 month low of $3.05 and a 12 month high of $9.01. The company has a market cap of $225.61 million, a price-to-earnings ratio of -1.93 and a beta of 1.46. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31.

Wall Street Analysts Forecast Growth

ABEO has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research note on Monday, November 25th. Cantor Fitzgerald restated an “overweight” rating and issued a $18.00 price objective on shares of Abeona Therapeutics in a research note on Tuesday, October 29th. Finally, StockNews.com lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 9th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ABEO. Rosalind Advisors Inc. increased its holdings in Abeona Therapeutics by 4.7% in the 3rd quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock worth $11,578,000 after acquiring an additional 82,000 shares during the last quarter. Western Standard LLC increased its stake in shares of Abeona Therapeutics by 7.0% in the third quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock worth $10,732,000 after purchasing an additional 110,998 shares in the last quarter. Citigroup Inc. increased its stake in shares of Abeona Therapeutics by 10.1% in the third quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock worth $3,897,000 after purchasing an additional 56,332 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Abeona Therapeutics by 581.6% in the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock valued at $2,134,000 after purchasing an additional 429,456 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Abeona Therapeutics by 21.7% during the 3rd quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock valued at $2,942,000 after buying an additional 83,050 shares in the last quarter. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.